ReviewImmunologic research2013
Myeloid derived suppressor cells in physiological and pathological conditions: the good, the bad, and the ugly.
Review in Immunologic research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed.
- G-CSF and Exenatide Might Be Associated with Increased Long-Term Survival of Allogeneic Pancreatic Islet Grafts.PloS one · 2016 · on this mapTrial
- Mycobacterium tuberculosis-specific T cells restrain anti-cancer drug-induced neutrophilic lung inflammation in tuberculosis.Nature communications · 2025Article
- Chemotherapy: A partnership with immunotherapy in non-small cell lung cancer.Thoracic cancer · 2023Review
- Role of voltage-gated proton channel (Hv1) in cancer biology.Frontiers in pharmacology · 2023Review
- Expression of HProceedings of the National Academy of Sciences of the United States of America · 2022Article
- Tertiary lymphoid structure and B-cell-related pathways: A potential target in tumor immunotherapy.Oncology letters · 2021Review
- Co-localization of CD169Oncoimmunology · 2020Article
- Aptamers against mouse and human tumor-infiltrating myeloid cells as reagents for targeted chemotherapy.Science translational medicine · 2020Article
- Tertiary Lymphoid Organs in Cancer Immunology: Mechanisms and the New Strategy for Immunotherapy.Frontiers in immunology · 2019Review
- Myeloid Cell Crosstalk Regulates the Efficacy of the DNA/ALVAC/gp120 HIV Vaccine Candidate.Frontiers in immunology · 2019Article
- The Reversal of Immune Exclusion Mediated by Tadalafil and an Anti-tumor Vaccine Also Induces PDL1 Upregulation in Recurrent Head and Neck Squamous Cell Carcinoma: Interim Analysis of a Phase I Clinical Trial.Frontiers in immunology · 2019Article
- Myeloid-Derived Suppressor Cells Are Regulated by Estradiol and Are a Predictive Marker for IVF Outcome.Frontiers in endocrinology · 2019Article
- Alterations in arginine and energy metabolism, structural and signalling lipids in metastatic breast cancer in mice detected in plasma by targeted metabolomics and lipidomics.Breast cancer research : BCR · 2018Article
- Clarithromycin expands CD11b+Gr-1+ cells via the STAT3/Bv8 axis to ameliorate lethal endotoxic shock and post-influenza bacterial pneumonia.PLoS pathogens · 2018Article
- Phenotypic and Functional Diversities of Myeloid-Derived Suppressor Cells in Autoimmune Diseases.Mediators of inflammation · 2018Review
- Presence of Infected Gr-1Frontiers in immunology · 2018Article
- Demethylating agent decitabine disrupts tumor-induced immune tolerance by depleting myeloid-derived suppressor cells.Journal of cancer research and clinical oncology · 2017Article
- [The progress of studying the mechanisms of immune cells in the regulation of non-alcoholic fatty liver diseases].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2017Review
- Myeloid-derived suppressor cells can be efficiently generated from human hematopoietic progenitors and peripheral blood monocytes.Immunology and cell biology · 2017Article
- Immunosuppressive myeloid-derived suppressor cells are increased in splenocytes from cancer patients.Cancer immunology, immunotherapy : CII · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myeloid derived suppressor cells (MDSCs), a heterogeneous population of myeloid progenitors, are recognized as a key element in tumor escape and progression. The importance of MDSCs in human malignancies has been demonstrated in recent years, and new approaches targeting their suppressive/tolerogenic action are currently being tested in both preclinical model and clinical trials. However, emerging evidence suggests that MDSCs may play a prominent role as regulator of the physiologic, the chronic, and the pathologic immune responses. This review will focus on the biology of MDSC in light of these new findings and the possible role of this myeloid population not only in the progression of the tumor but also in its initiation.
Indexed as
Identifiers
24203443What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.